Recruiting PHASE1 INTERVENTIONAL 1-arm NCT03631953

Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas (ALTREM)

Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas: Phase 1 Study

Sponsor: Assistance Publique Hopitaux De Marseille

Interventions Alpelisib Blood sample MRI Trametinib

Updated 6 times since 2018 Last updated: Aug 5, 2024 Started: Sep 30, 2019 Primary completion: Jan 29, 2026 Completion: Jan 29, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Meningioma and is currently actively recruiting participants. Assistance Publique Hopitaux De Marseille leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE1

Status: Unknown → Recruiting
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Nov 2022 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jan 2021 — Nov 2022 [monthly]

Recruiting PHASE1
Jun 2020 — Jan 2021 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Sep 2018 — Jun 2020 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assistance Publique Hopitaux De Marseille

Data source: Assistance Publique Hopitaux De Marseille

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Marseille, France